Search research articles
Contact Us
Filters
Showing results (1-10 of 39) with videos related to
Page
of 4
Sort By:
Advances in Experimental Medicine and Biology
|
August 31, 2016
Non-coding RNAs Functioning in Colorectal Cancer Stem Cells
Daniele Fanale, Nadia Barraco, Angela Listì, et al.
Translational Lung Cancer Research
|
June 13, 2022
Optimizing the clinical management of <i>EGFR</i>-mutant advanced non-small cell lung cancer: a literature review
Francesco Passiglia, Paolo Bironzo, Valentina Bertaglia, et al.
PPAR Research
|
February 10, 2017
Potential Role of ANGPTL4 in the Cross Talk between Metabolism and Cancer through PPAR Signaling Pathway
Laura La Paglia, Angela Listì, Stefano Caruso, et al.
Critical Reviews in Oncology/Hematology
|
March 23, 2017
EGFR inhibition in NSCLC: New findings…. and opened questions?
Francesco Passiglia, Angela Listì, Marta Castiglia, et al.
International Journal of Cancer
|
October 29, 2017
Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab
Francesco Passiglia, Antonio Galvano, Sergio Rizzo, et al.
Clinical Lung Cancer
|
September 12, 2020
A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non-small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design
Francesco Passiglia, Paolo Bironzo, Luisella Righi, et al.
Cancers
|
June 2, 2021
Pathological Characterization of Tumor Immune Microenvironment (TIME) in Malignant Pleural Mesothelioma
Francesca Napoli, Angela Listì, Vanessa Zambelli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 18, 2023
Niraparib plus Dostarlimab in Pleural Mesothelioma or Non-Small Cell Lung Cancer Harboring HRR Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial
Francesco Passiglia, Luisella Righi, Paolo Bironzo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 18, 2023
The Role of Germline Mutations in Thoracic Malignancies: Between Myth and Reality
Giovanni Farinea, Veronica Crespi, Angela Listì, et al.
Therapeutic Advances in Medical Oncology
|
May 31, 2016
Nintedanib in NSCLC: evidence to date and place in therapy
Giuseppe Bronte, Francesco Passiglia, Antonio Galvano, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 39) with videos related to
Sort By:
Page
of 4
Advances in Experimental Medicine and Biology
|
August 31, 2016
Non-coding RNAs Functioning in Colorectal Cancer Stem Cells
Daniele Fanale, Nadia Barraco, Angela Listì, et al.
Translational Lung Cancer Research
|
June 13, 2022
Optimizing the clinical management of <i>EGFR</i>-mutant advanced non-small cell lung cancer: a literature review
Francesco Passiglia, Paolo Bironzo, Valentina Bertaglia, et al.
PPAR Research
|
February 10, 2017
Potential Role of ANGPTL4 in the Cross Talk between Metabolism and Cancer through PPAR Signaling Pathway
Laura La Paglia, Angela Listì, Stefano Caruso, et al.
Critical Reviews in Oncology/Hematology
|
March 23, 2017
EGFR inhibition in NSCLC: New findings…. and opened questions?
Francesco Passiglia, Angela Listì, Marta Castiglia, et al.
International Journal of Cancer
|
October 29, 2017
Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab
Francesco Passiglia, Antonio Galvano, Sergio Rizzo, et al.
Clinical Lung Cancer
|
September 12, 2020
A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non-small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design
Francesco Passiglia, Paolo Bironzo, Luisella Righi, et al.
Cancers
|
June 2, 2021
Pathological Characterization of Tumor Immune Microenvironment (TIME) in Malignant Pleural Mesothelioma
Francesca Napoli, Angela Listì, Vanessa Zambelli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 18, 2023
Niraparib plus Dostarlimab in Pleural Mesothelioma or Non-Small Cell Lung Cancer Harboring HRR Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial
Francesco Passiglia, Luisella Righi, Paolo Bironzo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 18, 2023
The Role of Germline Mutations in Thoracic Malignancies: Between Myth and Reality
Giovanni Farinea, Veronica Crespi, Angela Listì, et al.
Therapeutic Advances in Medical Oncology
|
May 31, 2016
Nintedanib in NSCLC: evidence to date and place in therapy
Giuseppe Bronte, Francesco Passiglia, Antonio Galvano, et al.
Page
of 4